and fertility-sparing surgery ($p=0.001$) but not with the tumor histology ($p=0.215$).

**Conclusion** The study delineated two different patient profiles related to the tumor pattern of growth. The exophytic pattern was associated with the presence of invasive and non-invasive peritoneal implants, an advanced FIGO stage, without impact on DFS. Identification of the BOT pattern during preoperative workup could be useful for better surgical planning.

**2022-RA-1527-ESGO** **RELIABILITY OF IOTA ADNEX MODEL IN BORDERLINE OVARIAN TUMORS, A SINGLE CENTER STUDY**

1Humaira Aziz, 2Rozilla Sadia Khan, 3Guilnaz Shafqat, 4Aliya Begum Aziz. 1Gynae-Oncology, Aga Khan University Hospital Karachi Pakistan, karachi, Pakistan; 2Obstetrics and Gynaecology, Aga Khan University Hospital, Karachi, Pakistan; 3Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan

10.1136/ijgc-2022-ESGO.737

**Introduction/Background** The discrimination of borderline ovarian tumor (BOT) is challenging Ultrasonography (US) is the most essential imaging modality for distinguishing ovarian masses but depends on the experience of radiologists. In 2014, the IOTA group carried out the assessment of different neoplasia’s in the Adnex Model. It was used to discriminate benign, BOTs, stage I, stage II-IV invasive ovarian cancer, and secondary metastatic cancer. This study aims to evaluate the efficacy of the Adnex model in the determination of BOTs.

**Methodology** This was a retrospective study, medical records of histopathologically proven cases of BOTs were included from the year 2009 to 2021. The ultrasound and clinical findings were entered in an online Adnex calculator. These results were used to calculate the absolute risk predicting the probability of mass being as BOT.

**Results** A total of 22 cases of BOT were included. Efficacy in terms of sensitivity of the Adnex model for preoperative diagnosis of BOTs was 18.2% [95%CI: 7.31–38.52]. Performance of the Adnex model based on absolute risk (AR) improves with a selection of a more inclusive cut-off value, varying from 4.5% (1/22) correctly classified case of BOT with the cut-off 20%, 18.2% (4/22) with the cut-off 10% and up to 53.5% (12/22) classified cases of BOT with cut off value of 3%. Similarly, relative risk (RR) was also used to classify the BOT, but only 4 (18.2%) cases were identified correctly.

**Conclusion** More encompassing cut-off values allow the model to differentiate BOTs better. The calculation based on RR or AR with a cut-off value of at least 10% should be used when evaluating BOTs. The IOTA Adnex model did not perform well in predicting cases of BOTs that were histopathologically proven in terms of sensitivity.

**2022-RA-1528-ESGO** **CARCINOID TUMORS OF THE OVARY, A RARE NEOPLASM: DESCRIPTION OF CASES AND REVIEW OF LITERATURE**

Marta Heras Garcia, Rosa Maria Alvarez Lopez, Silvia Hernandez Bonilla, Eugenia Janeho Dorrego. Hospital Santa Cristina, Madrid, Spain

10.1136/ijgc-2022-ESGO.738

**Introduction/Background** Ovarian carcinoid tumors are rare neoplasms that account for 0.8–1.2% of all ovarian cancer. In 15% of cases there is a mature teratoma on the contratralateral ovary. Suspicion prior to surgery is rare, since its clinical presentation does not differ from other types of ovarian cancer unless there is carcinoid syndrome. Accurate diagnosis is difficult and needs for immunohistochemistry. Treatment is based on surgical resection, since the role of chemotherapy remains unclear. Their prognosis is excellent when diagnosed at early-stage, but long-term surveillance is necessary since late recurrence is possible.

**Methodology** Five patients diagnosed of ovarian carcinoid at Hospital Santa Cristina in Madrid, Spain are included. Four patients were diagnosed of primary ovarian carcinoid tumor and one patient was diagnosed of ovarian metastases of an appendicular carcinoid tumor.

**Results** 2 patients were premenopausal and presented unilateral mass suspicious of teratoma, so they underwent unilateral adnexectomy, with postoperative diagnosis of ovarian carcinoid tumor stage IA. Long-term follow-up evidenced contralateral cyst > 10 years after treatment, so both patients required adnexectomy, with no presence of disease recurrence. 2 patients were postmenopausal. The first had an ovarian mass that suggested teratoma, so she underwent bilateral adnexectomy plus hysterectomy; postoperatively she presented heart carcinoid syndrome, and required surgical correction. The second patient had suspicion for peritoneal carcinomatosis, so she underwent complete cytoreductive surgery. Both were stage IA. The fifth patient had an ovarian recurrence of an appendicular carcinoid. All patients diagnosed of primary ovarian carcinoid were free of disease when data were collected.

**Conclusion** Ovarian carcinoids represent a rare entity that requires surgery and is often diagnosed postoperatively. Prognosis is excellent when diagnosed at early-stage, but survival is low if carcinoid tumor is advanced-stage or metastases from a non-ovarian origin. Late relapses are possible.

**2022-RA-1540-ESGO** **MITO 25.1: A RANDOMIZED, MOLECULAR DRIVEN PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL-BEVACIZUMAB VS CARBOPLATIN-PACLITAXEL-BEAVCAZUMAB-RUCAPARIB VS CARBOPLATIN-PACLITAXEL-RUCAPARIB, SELECTED ACCORDING TO HRD STATUS, IN PATIENTS WITH ADVANCED (STAGE III B-C-IV) OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER**

1Lucia Musacchio, 2Vanda Salutari, 3Sandro Pignata, 4Giorgio Valabrega, 5Laura Zavallone, 6Gennaro Cormio, 7Anna Maria Mosconi, 8Serena Giolitto, 9Caterina Ricci, 10Camilla Nero, 11Maria Vittoria Carbone, 12Viola Ghizzone, 13Roberto Sori, 14Salvatore Siena, 15Francesca Tronconi, 16Antonella Savarese, 17Giovanni Scambia, 18Domenica Lorusso. 1Department of Gynecology and Obstetrics, Policlinico Agostino Gemelli IRCCS, Rome, Italy; 2Department of Gynecology and Obstetrics, Policlinico Sant'Orsola Malpighi, Bologna, Italy; 3Department of Gynecology, Policlinico Sant'Ospedale Maggiore Policlinico Sant'Ospedale Maggiore, Bologna, Italy; 4Department of Obstetrics and Gynecology, Istituto Nazionale dei Tumori Regina Elena, Rome, Italy; 5Istituto di Candiolo, IRCCS, Turin, Turin, Italy; 6Interdisciplinary Department of Medicine, Bari, Italy; 7Medical Oncology, Ospedale S. Maria della Misericordia, Perugia, Italy; 8Fondazione Poli Chirurgico Agostino Gemelli IRCCS, Rome, Italy; 9Fondazione Poli Chirurgico Agostino Gemelli IRCCS, Rome, Italy; 10Fondazione Policlinico A.Gemelli IRCCS, Rome, Italy; 11CRO Aviano, Aviano, Italy; 12Ospedale Niguarda Milano, Milan, Italy; 13Marche Polytechnic University, Ancona, Italy; 14Istituto Nazionale dei Tumori Regina Elena, IFO, Rome, Italy

10.1136/ijgc-2022-ESGO.739

**Introduction/Background** Poly (ADP-ribose) polymerase (PARP) inhibitors alone and in combination with Bevacizumab have shown significant clinical benefit as maintenance therapy in